Skip to main content
B

BioElectronics Corporation — Investor Relations & Filings

Ticker · BIEL ISIN · US09062H1086 Manufacturing
Open in API
Filings indexed 4 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country US United States of America
Listing — BIEL

About BioElectronics Corporation

BioElectronics Corporation is a leading developer and manufacturer of non-invasive electroceutical medical devices. The company specializes in creating electromagnetic therapeutic applications, primarily focusing on wearable neuromodulation technologies. These devices are engineered to provide non-pharmacological treatment solutions by safely mitigating neurological diseases, treating soft tissue trauma, and effectively reducing chronic pain and inflammation. BioElectronics positions itself as an innovator in the electroceutical field, aiming to improve patient quality of life through advanced, wearable technology.

Recent filings

Filing Released Lang Actions
ActiPatch Expands to Taiwan, Challenging Traditional Pain Management With Drug-Free Innovation
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing the commercial launch and distribution of a medical device in Taiwan. It contains no financial results, governance changes, share transactions, or regulatory form filings. As it does not fit any specific financial or corporate event category, it falls into the general “Regulatory Filings” fallback category.
2026-04-22 English
BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
Regulatory Filings Classification · 1% confidence The document is a press release issued by BioCorRx, Inc. announcing the issuance of a U.S. patent for its biodegradable naltrexone implant technology. It provides details on the patent, the company's intellectual property strategy, and background information on its clinical programs. As this is a corporate news announcement regarding business operations and intellectual property rather than a financial report, dividend notice, or regulatory filing, it falls under the general category of corporate news/regulatory announcements.
2026-03-11 English
BioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without Bupropion
Regulatory Filings Classification · 1% confidence The document is a press release issued by BioCorRx, Inc. announcing the initiation of a Phase 1 clinical study for their product BICX104. It follows the standard format of a corporate press release, providing details on the study, company background, and forward-looking statements. It does not constitute a formal financial report, audit, or regulatory filing, but rather a corporate news announcement regarding operational/clinical progress. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate news announcement.
2026-01-14 English
BioCorRx Announces Appointment of Louis Lucido as Board Chair
Board/Management Information Classification · 1% confidence The document is a corporate press release announcing the appointment of a new Board Chair (Louis Lucido) and a leadership transition. This falls directly under the category of announcements regarding changes in the company's board of directors or senior management.
2026-01-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.